Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Receivables (2017 - 2025)

Entera Bio has reported Receivables over the past 9 years, most recently at $126000.0 for Q1 2025.

  • For the quarter ending Q1 2025, Receivables changed N/A year-over-year to $126000.0, compared with a TTM value of $126000.0 through Mar 2025, changed N/A, and an annual FY2024 reading of $126000.0, changed N/A over the prior year.
  • Receivables came in at $126000.0 for Q1 2025, roughly flat from $126000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $979000.0 in Q2 2021 to a low of $29000.0 in Q1 2023.
  • Median Receivables over the past 5 years was $196500.0 (2021), compared with a mean of $215214.3.
  • The sharpest move saw Receivables surged 1897.96% in 2021, then crashed 87.11% in 2023.
  • Over 5 years, Receivables stood at $183000.0 in 2021, then surged by 34.43% to $246000.0 in 2022, then plummeted by 88.21% to $29000.0 in 2023, then skyrocketed by 334.48% to $126000.0 in 2024, then changed by 0.0% to $126000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Receivables are $126000.0 (Q1 2025), $126000.0 (Q4 2024), and $42000.0 (Q3 2024).